At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
TORS +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer
In Brief
A Phase 2 clinical trial evaluating TORS and Adjuvant Radiation Therapy for Oropharyngeal Cancer. Completed, enrolled 60 participants across 1 site.
Detailed Summary
To determine 2-year local (primary tumor site) control and toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx. To determine acute and long-term toxicity rates in patients receiving adjuvant RT post-TORS, omitting the primary tumor bed, in patients with completely resected, HPV-positive SCCA of the oropharynx.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOropharyngeal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2014
First PostedJun 2014
Primary CompletionFeb 2018
TodayJul 2026
First PostedJun 10, 2014
Enrollment StartFeb 1, 2014
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 12.1 years ago
Interventions
TORSprocedure
Adjuvant Radiation Therapyradiation